The number of installments for satisfying a milestone payment associated with a collaborative agreement.

No definition available.

Name:	aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments
Namespace Prefix:	aciu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment(s) received for milestone payments associated with a collaborative agreement.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementMilestonePaymentReceived
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod
Namespace Prefix:	aciu_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The total potential value of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementPotentialValue
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The number of representatives in a joint steering committee by each party as per the agreement.

+ References

No definition available.

+ Details

Name:	aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty
Namespace Prefix:	aciu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity’s future performance).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 105
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 116
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 105
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard
-URIDate 2025-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 105
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ContractAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 78
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.

+ References

+ Details

Name:	ifrs-full_ReceivablesFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 120
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsCommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_ResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_RightOfUseLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyFirstAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=aciu_Quarter32019Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=aciu_March312020Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillySecondAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=aciu_UponFirstPatientDosedInPhase2ClinicalStudyOfLicensedProductInU.s.OrEu.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contract revenues - Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details) SFr in Thousands		3 Months Ended			12 Months Ended			78 Months Ended	83 Months Ended
	Jan. 23, 2019 CHF (SFr)	Mar. 31, 2020 CHF (SFr) installment	Sep. 30, 2019 CHF (SFr) installment	Mar. 31, 2019 CHF (SFr)	Dec. 31, 2025 CHF (SFr) item	Dec. 31, 2024 CHF (SFr)	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2025 CHF (SFr)	Dec. 31, 2025 CHF (SFr)
Contract revenues
Revenue from contracts with customers					SFr 3,573	SFr 27,309	SFr 14,801
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly and Company
Contract revenues
Milestone payment received				SFr 80,000
Period to provide notice of termination of agreement					3 months
Number of representatives in joint steering committee by each party \| item					3
Revenue from contracts with customers					SFr 0	SFr 0	SFr 0
Deferred income					0			SFr 0	SFr 0
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly and Company \| Clinical and Regulatory \| Maximum
Contract revenues
Transaction price					880,000			880,000	880,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly and Company \| Commercial \| Maximum
Contract revenues
Transaction price					SFr 900,000			900,000	900,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly and Company \| Research and Development
Contract revenues
Deferred research and development costs	SFr 6,900
Revenue from contracts with customers									SFr 6,900
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly and Company \| Right-of-use License
Contract revenues
Revenue from contracts with customers	SFr 73,100							SFr 40,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, First Amendment
Contract revenues
Total potential collaboration agreement value			SFr 60,000
Number of installments \| installment			2
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, First Amendment \| Quarter 3, 2019
Contract revenues
Milestone payment receivable			SFr 30,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, First Amendment \| March 31, 2020
Contract revenues
Milestone payment receivable		SFr 30,000	SFr 30,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, Second Amendment
Contract revenues
Number of installments \| installment		2
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, Second Amendment \| March 31, 2020
Contract revenues
Milestone payment receivable		SFr 10,000
Morphomer Tau Small Molecule \| 2018 License Agreement with Eli Lilly, Second Amendment \| Upon first patient dosed in a Phase 2 clinical study of a licensed product in the U.S. or EU.
Contract revenues
Milestone payment receivable		SFr 60,000